{"id":"W4366083620","doi":"10.1182/bloodadvances.2022009260","title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; MorphoSys; Juno Therapeutics; Adaptive Biotechnologies; Celltrion; Celgene; Alimera Sciences; BeiGene; MEI Pharma; Sunesis; TG Therapeutics; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Pfizer; Incyte; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Yuhan; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Internal medicine; Medicine; Oncology; Cancer research; Gastroenterology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007451788,0.0002999253,0.0008473457,0.0002227239,0.0002265627,0.000331984,0.0001688605,0.0002132183,0.0006116031],"category_scores_gemma":[0.0005390671,0.000172304,0.0002343746,0.0001898747,0.0002350618,0.000270181,0.0001556114,0.0005351665,0.0002255593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000261146,"about_ca_system_score_gemma":0.0002734652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003543625,"about_ca_topic_score_gemma":0.001187597,"domain_scores_codex":[0.9997563,0.0001065347,0.00001546828,0.00003740707,0.0000358346,0.00004842057],"domain_scores_gemma":[0.9997967,0.00004433601,0.00004107596,0.00001779795,0.00001222886,0.00008785757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.119916,0.0131117,0.2800936,0.0004781341,0.0007203787,0.002531051,0.000814396,0.002389657,0.2093747,0.0002120144,0.003485662,0.3668727],"study_design_scores_gemma":[0.02939571,0.262567,0.6789979,0.00005200539,0.0004836263,0.004251143,0.000202569,0.004643649,0.01213881,0.0001778018,0.007045384,0.00004433095],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99884,0.0005001005,0.00009914052,0.00003609425,0.000005188052,0.00008264004,0.00006615592,0.00001470094,0.0003558777],"genre_scores_gemma":[0.9991257,0.0002318499,0.0001901512,0.00007109118,0.00002039027,0.00005232045,0.0001566994,0.000002165488,0.0001497331],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008473457,"threshold_uncertainty_score":0.00394094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008757305009623545,"score_gpt":0.261308908155294,"score_spread":0.2525516031456705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}